tirzepatide latest news FDA confirms shortage is still over, gives compounders a grace period FDA says the tirzepatide weight-loss
Description
GLP-1RAs produce more frequent and severe side effects when administered through larger doses or quicker titration schedules
* Correspondence: Ming-Hsien Tsai, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Diabetologia 63:221228
The letter does not explain a reason for the change, but does notify recipients that coverage for the drug will end Dec
There are other non-hormonal therapies available as well
